Concepedia

Gail Lynn Shaw Wright

GL

Statistics

Publications

4

Citations

271

H-Index

4

Active since

2018

Affiliations

University of California, San Francisco(Current)

Sarah Cannon

Seoul National University Hospital

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

UCSF Helen Diller Family Comprehensive Cancer Center

Gail Lynn Shaw Wright is an author at University of California, San Francisco specializing in metastatic breast cancer treatment, pharmacology, and metastatic breast cancer.

Publications per year

2018–2024

4

Publications

4

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

, , +17

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

Hope S. Rugo, Seock‐Ah Im, Gail Lynn Shaw Wright et al. · Journal of Clinical Oncology · 2019 · 80 citations

, , +17

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

Erika Hamilton, Judy S. Wang, Timothy Pluard et al. · Journal of Clinical Oncology · 2021 · 37 citations

, , +16

Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study

Denise A. Yardley, Lowell L. Hart, Patrick J. Ward et al. · Clinical Breast Cancer · 2018 · 14 citations

, , +17

1–4 of 4